Claim · model-written summary
The authors recommend pharmaceutical or nutraceutical use of cauliflower by-products.
- Taxon
- cauliflower
Brassica oleracea var. botrytist0 - Outcome
- should be used for pharmaceutical or nutraceutical purposese0
Not reportedMaterialGeneCompoundOrgan / stageInteractorInteractor roleSecond interactorSecond interactor roleTreatmentComparatorSettingDirectionValueQualifier
Organisms pictured · Representative pictures of the matched species, not figures from the paper.
Verbatim
e0“they should no longer be regarded as mere by-products and should be used for pharmaceutical or nutraceutical purposes”
t0“cauliflower”
Title
Jacinta Collado-González; María Carmen Piñero; Ginés Otalora; et al. Antioxidants 2022. doi:10.3390/antiox11050958
Other claims from this paper (9)
- Intervention effect Elevated CO2 plus 2.5 mM putrescine before heat produced the highest cauliflower biomass, 20% above control.
- Intervention effect Outer leaves under elevated CO2 and putrescine before heat showed the highest sugar biosynthesis, 20%.
- Observation Outer cauliflower leaves contained 208.6 nmoles g−1 FW polyamines.
- Observation Inner cauliflower leaves contained 124.3 nmoles g−1 FW polyamines.
- Observation Outer cauliflower leaves contained 1070.2 mg GAE per 100 g FW phenolic compounds.
- Observation Inner cauliflower leaves contained 772.0 mg GAE per 100 g FW phenolic compounds.
- Intervention effect The strategy increased polyamines in outer cauliflower leaves by 68%.
- Intervention effect The strategy increased phenolic compounds in outer cauliflower leaves by 39%.
- Intervention effect The strategy increased antioxidant activity in outer leaves by 3%.